Instructions for Spiolto Respimat (Olodaterol, Tiotropium bromide) dose solution for inhalation 4 ml
English product name
Spiolto® Respimat®
Release Form
Solution for inhalation dosed
Description Spiolto Respimat
The inhalation solution is transparent, colorless or almost colorless.
1 dose
olodaterol 2.5 ug
which corresponds to the contents of olodaterol hydrochloride 2.736 μg,
thiotropy bromide 2.5 ug
which corresponds to the content of 3.124 μg bromidate thiotropy,
Auxiliary substances: benzalkonium chloride solution - 2.2 μg (respectively 1.1 μg of chloride benzalkonium), 1.1 μg of dehydrate dehydrate, 1M of chlorohydric acid to pH 2.9, water purified - up to 11.05 mg.
60 inhalation doses (30 therapeutic doses) - cartridges (1) with a capacity of 4.5 ml, placed in an aluminium cylinder, complete with an inhaler Respimat® - cardboard packs.
ATC codes
R03AL06 Olodaterol and Thiotropy Bromide
Clinical-pharmacological groups / Group affiliation
Broncholytic preparation
Active substance
- thiotropy bromide
- olodaterol
Pharmaco-therapeutic group Spiolto Respimat
Broncholytic agent combined (long-acting beta2-adrenomimetic + m-cholinoblocker)
Storage Conditions
The drug should be stored in a place inaccessible to children at a temperature not higher than 25 ° C. Do not freeze.
Best before date
The shelf life is three years. Use for three months after the first inhalation.
Pharmacological effect Spiolto Respimat
Combined broncholytic drug. The long-acting beta2-adrenomimetic olodaterol and the thiotropic bromide m-cholinoblocker provide complementary bronchodilation as a result of the different mechanism of action of active substances and the different localization of target receptors in the lungs.
Testimony Spiolto Respimat
long-term maintenance therapy in patients with COPD, chronic bronchitis, pulmonary emphysema;
to reduce obstruction of the respiratory tract and associated shortness of breath;
to reduce the frequency of exacerbations; to improve the portability of physical exertion and the quality of life.
Method of use, course and dosage Spiolto Respimat
The recommended therapeutic dose is two inhalations of Respimat® inhaler spray (5 ug/therapeutic dose of bromine thiotropy and 5 ug/therapeutic dose of olodaterol) 1 time/day at the same time of day.
In elderly patients, the drug Spiolto® Respimat® can be used at the recommended dose.
In patients with mild to moderate liver failure, Spiolto® Respimate® can be used in the recommended dose. Data on the use of olodaterol in patients with severe liver failure are not available.
In patients with kidney disorders, the drug Spiolto® Respimat® can be used at the recommended dose.
Patients with moderate to severe renal failure who use Spiolto® Respimat® should be carefully monitored by a doctor.
Rules of application of Spiolto® Respimat inhaler®
Before using the drug, you should study the rules of the use of the inhaler ® Respimat®.
The inhaler is intended for use once a day. Each time you use it, you should do two inhalations.
Use in children
The use of the drug is contraindicated for children and adolescents under the age of 18 (due to the lack of data on effectiveness and safety).
- Nosology (ICD codes)
- J43
- Emphysema
- J44
- Other chronic obstructive pulmonary disease